SNO2020 | ERC1671 vaccines co-treat of relapsed GBM
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
SNO2020 | ERC1671 vaccines co-treat of relapsed GBM
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- What is the difference between Atorvastatin and Rosuvastatin?
- How long can the patient live after heart stent surgery?
SNO2020 | ERC1671 vaccines co-treat of relapsed GBM.
SNO2020 | ERC1671 vaccine combination therapy has good results in the treatment of relapsed GBM.
According to a press release “The ERC1671 Vaccine Shows Promise in Recurrent GBM” reported by PracticeUpdate on November 25, 2020, the Daniela Bota team of the University of California, Irvine, at the 2020 Neuro-Oncology Annual Conference ( SNO) meeting announced the preliminary results of its double-blind, placebo-controlled randomized phase II clinical study.
The researchers found that compared with placebo, ERC1671 pretreatment and CD4+ T lymphocyte counts in peripheral blood have a stronger correlation with overall survival.
In relapsed glioblastomas without bevacizumab and bevacizumab resistance There were significant effects in patients with cell tumors, and there was no difference in the incidence of adverse reactions between the experimental group and the placebo control group.
Professor Bota’s team is evaluating the combined therapy of ERC1671 with granulocyte-macrophage colony stimulating factor and cyclophosphamide as an adjuvant therapy for bevacizumab to treat recurrent glioblastoma.
Up to now, 22 patients with recurrent glioblastoma who have not been treated with bevacizumab have been enrolled and randomly assigned to ECR1671/granulocyte-macrophage colony stimulating factor/cyclophosphamide combined with bevacizumab treatment Group and placebo combined with bevacizumab treatment group.
The median age of the enrolled patients was 56.5 (33-74) years, of which 7 were women (32%), and the average KFS score was 82.3 (70-100).
Among 22 patients, 2 patients stopped before completing 1 cycle of treatment, and 2 patients were still under blind treatment. Eighteen patients were unblinded due to tumor progression: 8 patients received ERC1671 combination therapy, and 10 patients received placebo.
Among the patients who received placebo, 5 were switched to ERC1671 combination therapy after progression, and only 1 of 18 did not die.
The median survival of 8 unblinded patients randomly assigned to the ERC1671 combination treatment group was 264.5 days (calculated from the beginning of treatment), while the median survival of 5 patients who were randomly assigned to the placebo group and did not switch to ERC1671 combination therapy The period is 182 days.
The median survival time of all 13 patients who received ERC1671 combination therapy (including patients initially assigned to ERC1671 combination therapy group and placebo patients who switched to ERC1671 combination therapy after progression) was 328 days.
Professor Bota said that ERC1671 is an allogeneic/autologous vaccine. It is a mixture of intact, inactivated tumor cells and tumor cell lysates.
The vaccine is believed to enhance the ability of the patient’s immune system to fight tumors.
ERC1671 contains autologous tumor cells and allogeneic tumor cells. The allogeneic tumor cells and cell lysates are derived from the glioma tumor tissues of three donor patients.
If approved, ERC1671, which is still under research, will be used for WHO grade 4 glioma (glioblastoma multiforme and glioma) when all other traditional treatment methods fail.
The patient’s response to ERC1671 has nothing to do with the methylation status of the MGMT promoter.
ERC1671, as part of the combined treatment of glioblastoma multiforme and gliosarcoma, is being evaluated in a randomized, placebo-controlled phase II clinical trial in the United States. “Although the data is scarce, the data so far show that compared with placebo, ERC1671 pretreatment and CD4+ T lymphocyte counts in peripheral blood have a stronger correlation with overall survival,” Professor Bota concluded.
Preliminary clinical results on toxicity showed that there was no difference in the distribution of adverse events between ERC1671 vaccine and placebo. No adverse events of grade 4-5 were observed in either group. This research is ongoing, and another center is joining the research.
SNO2020 | ERC1671 vaccines co-treat of relapsed GBM
(source:internet, reference only)
Disclaimer of medicaltrend.org
